# Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis

> **NCT04587453** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 106 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tralokinumab
- **DRUG:** Placebo
- **OTHER:** Topical corticosteroids (TCS)

## Key facts

- **NCT ID:** NCT04587453
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-27
- **Primary completion:** 2021-07-06
- **Final completion:** 2021-07-15
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04587453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04587453, "Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04587453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*